Clinically Tested Cognitive Performance Supplement
The cognitive benefits of Neumentix™ Phenolic Complex K110-42 are supported by clinical research.
In a 90-day randomized, double-blind, placebo-controlled (RDBPC) study, people who took Neumentix showed better quality of working memory compared to subjects who took a placebo.1
People who took 900 mg per day showed:1
15% improvement in quality of working memory performance compared to placebo, as shown in graph below.
9% improvement in spatial working memory compared to placebo.
What does this mean for you?
Research suggests working memory can naturally decline about 10% per decade, starting as early as our 20s.2
Taking 900 mg of Neumentix per day may help optimize your working memory, which supports cognitive abilities such as attention, multi-tasking and complex thought.
Plant-based sleep support
Beyond the working memory health benefits of our spearmint, Neumentix has been shown to help people fall asleep easier and faster at night.
In the same 90-day RDBPC study, people who took 900 mg of Neumentix in the morning experienced significant improvements in falling asleep easier and faster at night compared to subjects who took a placebo.1
Safe and tolerable
Neumentix has been shown to be safe in animal toxicity and genotoxicity studies.3 In all human clinical trials, Neumentix has been shown to be well tolerated with no adverse side effects related to the study product.1,4
Our commitment to research
To date, Kemin has invested $1.5 million into Neumentix research and we continue to invest in an ongoing research program.
Our ongoing research program includes discovery and hypothesis-driven research. Our discovery program allows us to explore novel outcomes or new market segments, while our hypothesis-driven research program includes both small- and large-scale trials to elucidate and confirm efficacy, safety and mechanisms of action.
In addition to human clinical trials, Kemin’s Neumentix research program includes in vitro and in vivo studies targeting mechanism of action, brain health, cognition and behavioral outcomes.
Click here to request more details on the research behind Neumentix and the ongoing Neumentix research program.
1RDBPC three month study [Fonseca, B., et al. (2015). Neurology. Conference: 67th American Academy of Neurology Annual Meeting, AAN, 84.] evaluated healthy men and women between the ages of 50 to 70 with age-associated memory impairment. The study showed significant differences between active and placebo groups on improvements in working memory and ease of falling asleep. Claims based on 900 mg Neumentix containing 14.5% - 17.5% Rosmarinic Acid and 24.0 - 32.0% Phenolics (expressed as gallic acid equivalents) taken once daily for 12 weeks.
2Park, D. C., Lautenschlager, G., Hedden, T., Davidson, N. S., Smith, A. D., & Smith, P. K. (2002). Models of visuospatial and verbal memory across the adult life span.Psychology And Aging, 17(2), 299-320.
3Lasrado et al. (2015). Regulatory Toxicology and Pharmacology 71 (2015) 213-224.
4Nieman et al. (2015). Functional Foods in Health and Disease 5 (2015) 165-187.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Certain statements may not be applicable in all geographical regions. Product labeling and associated claims may differ based upon government requirements.